• Biogen abandons controversial Alzheimer's drug Aduhelm

    Biogen is discontinuing its Alzheimer's drug Aduhelm, which was approved in 2021 but became snarled in efficacy concerns and payers' refusals to cover the medication. 
  • How does your system manage rare disease patients? Becker's wants to hear.

    Sponsored
    Fill out this short survey here and attend our annual meeting for free.
  • Walgreens to lay off more corporate staff

    After laying off 5% of its corporate workforce in November, Walgreens will lay off 145 more workers, most of whom are corporate employees, the company confirmed to Becker's. 
  • 9 drugs now in shortage

    In January, nine more drugs fell into shortage, adding to the 300-some medications in short supply because of manufacturing delays, quality issues or high demand. 
  • Drugmaker recalls ADHD medication over pill mix up

    Azurity Pharmaceuticals has recalled one lot of Zenzedi — a drug used to treat narcolepsy and ADHD — after learning that at least one bottle contained a different drug. 
  • Experimental pain relief drug clears phase 3 metrics

    An experimental drug was produced clinically meaningful pain relief among surgical and non-surgical pain conditions, and the therapy could fill the gap between safe, low-efficacy medicines and opioid treatments, its manufacturer said Jan. 30. 
  • Michigan Medicine makes specialty pharmacy a strategic focus

    As the effects of the COVID-19 pandemic have lessened, officials at Ann Arbor-based Michigan Medicine, which includes University of Michigan Health and the university's medical school, have been able to invest in innovative care, including expanding its specialty and mail-order pharmacy program. Among the goals were increasing the number of prescriptions it fills annually through its in-house pharmacy, as well as reducing the time it takes to fill prescriptions for patients.
  • California system taps specialty pharmacy partner

    Sharp HealthCare, a seven-hospital system in San Diego, partnered with a specialty pharmacy solutions provider Jan. 30.
  • FDA sets end date for Paxlovid emergency use

    The FDA will end emergency use authorization of Paxlovid for adult patients March 8. 
  • OTC morning-after pill tied to 96% fewer related ED visits

    After the FDA approved the first over-the-counter emergency contraception in 2006, emergency department visits for the medication decreased by 96% over the next 14 years, according to a new study. 
  • Weight loss drugs show strides in reducing inflammation

    A new class of weight loss and diabetes drugs could reduce inflammation in the liver, kidneys, heart and even the brain, Nature reported Jan. 26. 
  • Novo Nordisk to stop selling Levemir insulin

    Levemir, one of the three types of long-acting basal insulins, is evacuating the U.S. market, and diabetes patient advocates told USA Today they're worried about using a new medication after nearly two decades. 
  • FDA clears Dupixent to treat esophageal condition in kids under 12

    The FDA has given the green light to Sanofi's drug Dupixent to be used as treatment in pediatric patients with chronic eosinophilic esophagitis, the pharmaceutical company announced Jan. 25.
  • Baptist Health nears completion of $40M central pharmacy

    Baptist Health's central pharmacy center is months away from filling up to 14,000 prescriptions a day, and the facility will be the nation's most automated central pharmacy. 
  • Walgreens, Vermont reach settlement over claims of unsafe pharmacy conditions

    Walgreens has reached a $275,000 settlement with the state of Vermont over allegations that medication and vaccination errors and other alleged violations created unsafe conditions for patients and staff at the chain's pharmacies across the state. 
  • Popular cough syrup recalled over contamination

     Haleon, the maker of Robitussin, has issued a voluntary recall of eight lots of three varieties of its cough medicines due to microbial contamination. 
  • Fake Ozempic tied to 3 cases of hypoglycemia: Reuters

    A regional poison control center suspects three cases of hypoglycemia in 2023 were linked to counterfeit versions of Ozempic, according to a Jan. 24 Reuters exclusive report.
  • Judge upholds Martin Shkreli's lifetime pharma ban

    A federal appeals court in New York has upheld an order that bars "pharma bro" Martin Shkreli from working in the pharmaceutical industry, according to court documents.
  • Tyson replaces CVS with Rightway for pharmacy benefits

    CVS Caremark will no longer handle pharmacy costs for Tyson Foods' 140,000 employees after the company cut its contract, CNBC reported Jan. 24. A few months ago, Blue Shield California curbed its yearslong partnership with the pharmacy benefit manager.
  • Majority of patients maintain weight loss after stopping medication, study reveals

    After discontinuing the use of semaglutide and liraglutide weight-loss medications, a majority of patients were able to maintain the same weight they were at when halting the use — or even continued to lose additional weight after one year, a new study revealed. 
  • How the Ozempic boom affects hospital pharmacies

    The viral popularity of Ozempic, Wegovy, and other diabetes and weight loss drugs is affecting hospital operations in a roundabout way. 

Featured Whitepapers

Featured Webinars